The IDI, located in Kampala, is a United Nations-recognized African Network for Drugs and Diagnostics Innovation (ANDI) Research Center of Excellence in infectious disease, as well as a key institutional research member of the Makerere University Medical Educational Partnership Initiative in Uganda. The IDI site focuses on HIV/TB and related conditions, and malaria.
IDI has collaborated with faculty from UCSF since its inception in 2004, and participated in large international trials in HIV treatment and prevention, malaria, tuberculosis (TB), hepatitis B and other infectious diseases. IDI has an annual budget of ~$20M, including National Institutes of Health and other international donors. By June 2015, IDI's program included 45 active research studies, consisting of 12 clinical trials, 18 observational studies, and 15 research capacity-building projects.
The research department has graduated 10 Ugandan PhD students and contributed to the training of more than 50 Ugandan Master's students through direct supervision of their research or research methodology courses.
IDI's research facility, the Translational Research Laboratory, is 800 square feet of newly renovated space at Makerere University. The Lab employs five full-time staff and supports six key areas of investigation: immunology, virology, molecular biology, microbiology, pharmacokinetics, and point of care diagnostics.
Site contact: Dr. Barbara Castelnuovo
Established in 1998 by Drs. M. Kamya (MU) and P. Rosenthal (UCSF), IDRC is a research collaboration between Makerere University and UCSF. The collaboration encompasses a broad range of research in infectious diseases, including malaria, HIV, and tuberculosis (TB), using molecular, clinical, epidemiological, and implementation science approaches.
The program includes a few dozen faculty at MU and UCSF and is managed by IDRC, with an annual budget of ~$9 million. Important projects include:
- Sustainable East Africa Research on Community Health (SEARCH), an NIH-funded study in Uganda and Kenya studying optimal provision of care for HIV and other medical problems
- Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM), an NIH Center of Excellence for Malaria Research with broad research centered on surveillance for malaria in the context of changing control practices in Uganda
- Prevention of Malaria and HIV Disease in Tororo, a set of randomized trials evaluating optimal malaria control practices for pregnant women and their children.
Other major programs study immune responses to malaria infection, antimalarial drug resistance, the pharmacokinetics and pharmacodynamics of antimalarial therapies, antimalarial treatment efficacy, antiretroviral therapy initiation, HIV-associated pneumonia, and TB transmission. An FIC-funded program for training of Ugandan scientists in malaria research has been in place since 2000, and has trained over 60 junior scientists.
Site contact: Catherine Tugaineyo